Table 3 Univariate and multivariate analysis of POD24 in newly diagnosed MM patients.

From: Progression of disease within 24 months (POD24) in multiple myeloma implicates poor prognosis and limitations of current prediction models for POD24

Clinical character

Univariate Analysis

Multivariate Analysis

HR(95%CI)

P value

HR(95%CI)

P value

Age(>60)

1.344(0.972–1.857)

0.074

  

Hemoglobin(< 100 g/L)

1.694(1.172–2.449)

0.005

1.395(0.920–2.115)

0.117

Lactate dehydrogenase (> 245U/L)

1.620(1.088–2.413)

0.018

1.435(0.956–2.155)

0.081

β2 -microglobulin (> 3.5 mg/L)

1.614(1.120–2.325)

0.010

1.155(0.758–1.760)

0.502

Creatinine(> 177 µmol/L)

1.079(0.735–1.583)

0.700

  

Blood calcium

(> 2.75 mmol/L)

1.886(1.166–3.051)

0.010

1.530(0.931–2.512)

0.093

Treatment (without bortezomib)

1.036(0.724–1.483)

0.845

  

Chromosomal abnormality

1.665(1.209–2.293)

0.002

1.747(1.251–2.439)

0.001

Non-transplantion

0.558(0.361–0.862)

0.009

0.521(0.331–0.819)

0.005

Back to article page